Integration of artificial intelligence into clinical workflows is enhancing oncology diagnostics and patient management. Adaptive Biotechnologies’ ClonoSeq minimal residual disease assay is now embedded into Flatiron Health’s electronic medical record platform, facilitating streamlined testing in community cancer centers. Meanwhile, AI-supported predictive models offer improved accuracy in breast and liver cancer risk assessments. Imaging and molecular data fusion with AI accelerates treatment decisions, while AI-guided drug discovery expedites novel therapeutic development.